Market Capitalization (Millions $) |
3 |
Shares
Outstanding (Millions) |
2 |
Employees |
- |
Revenues (TTM) (Millions $) |
- |
Net Income (TTM) (Millions $) |
-24 |
Cash Flow (TTM) (Millions $) |
1 |
Capital Exp. (TTM) (Millions $) |
0 |
Geovax Labs Inc
GeoVax Labs Inc. is a biotechnology company that focuses on developing innovative vaccines to prevent and treat infectious diseases, including HIV/AIDS. The company utilizes a unique vaccine platform called Modified Vaccinia Ankara-Virus Like Particle (MVA-VLP) to design and develop its vaccines. This platform allows for the production of non-infectious virus-like particles that mimic the target virus, triggering an immune response to provide protection against the actual virus.
GeoVax Labs' vaccines are designed to be safe, effective, and easy to produce, making them suitable for large-scale distribution. The company has dedicated significant efforts into developing an effective HIV/AIDS vaccine that can provide a durable and long-lasting immune response. Additionally, GeoVax Labs is exploring opportunities to apply its MVA-VLP platform for the development of vaccines against other infectious diseases, such as Zika, Ebola, and Lassa fever.
With a team of experienced scientists and researchers, GeoVax Labs is committed to advancing the field of vaccine development and public health. The company collaborates with various research institutions, government agencies, and pharmaceutical companies to accelerate the progress of its vaccine programs. By addressing global health challenges, GeoVax Labs strives to make a positive impact on the lives of millions of individuals worldwide.
Company Address: 1900 Lake Park Drive, Suite 380 Smyrna 30080 GA
Company Phone Number: 384-7220 Stock Exchange / Ticker: NASDAQ GOVX
GOVX is expected to report next financial results on March 22, 2024. |
|
|